Immuneering Corp Stock Price, News & Analysis

Immuneering Corporation (Nasdaq: IMRX) announced the appointment of Diana F. Hausman, M.D. to its Board of Directors, enhancing its leadership with her >20 years of clinical drug development experience. Dr. Hausman, previously Chief Medical Officer at Lengo Therapeutics, will contribute significantly to advancing Immuneering's pipeline, notably the lead candidate IMM-1-104, a dual-MEK inhibitor for RAS mutant tumors. Her extensive background in oncology showcases the company’s commitment to improving therapeutic options for cancer patients.

Immuneering Corporation (Nasdaq: IMRX) has revealed promising preclinical data for its lead product candidate, IMM-1-104, indicating its potential to inhibit tumor growth in NRAS mutant melanoma models. This data, which compares IMM-1-104 to binimetinib, suggests superior efficacy, achieving tumor growth inhibition rates between 74.9% and 99.9%. The company plans to submit an Investigational New Drug application to the FDA in Q3 2022 and aims to commence human clinical trials by Q4 2022. The findings underscore IMM-1-104’s potential as a therapeutic alternative in treating RAS mutant tumors.

Immuneering Corporation (Nasdaq: IMRX) has appointed Rimma Steinhertz, Ph.D., PMP, as Vice President of Project and Alliance Management, effective immediately. Dr. Steinhertz brings extensive experience in oncology and neurology, previously holding leadership roles at Glenmark Pharmaceuticals and Merck. In her new role, she will work with the leadership team to advance the clinical trials of IMM-1-104, a selective dual-MEK inhibitor targeting RAS mutant tumors. The company's strategy includes collaborations to enhance treatment approaches.

Immuneering Corporation (Nasdaq: IMRX) announced its inclusion in the Nasdaq Biotechnology Index (NBI), effective December 20, 2021. This addition, less than five months post-initial public offering, aims to enhance visibility within the investment community. CEO Ben Zeskind highlighted the promising performance of the company’s lead candidate, IMM-1-104, demonstrating tumor growth inhibition across multiple animal models. The firm focuses on developing treatments for solid tumors driven by oncogenic mutations, supported by a pipeline encompassing six other oncology and two neuroscience programs.

Immuneering Corporation (Nasdaq: IMRX) announced its participation in several December investor conferences to discuss its oncology pipeline and business strategy. Key events include the Piper Sandler Global Healthcare Conference and Evercore ISI HealthCONx Conference, where executives will engage in investor meetings and fireside chats. The company focuses on developing therapies that target oncogenic signaling pathways, notably with its lead product candidate IMM-1-104, aimed at advanced solid tumors. Immuneering emphasizes its proprietary platform driven by translational bioinformatics.

Immuneering Corporation (Nasdaq: IMRX) announced its participation in the upcoming Jefferies 2021 London Healthcare Conference, scheduled for November 16-19, 2021. Company executives, including CEO Ben Zeskind, will present virtually on November 18 at 08:00 GMT (03:00 AM ET). The presentation will highlight their innovative pipeline of oncology drug candidates, particularly focusing on their lead product, IMM-1-104, a selective dual-MEK inhibitor for advanced solid tumors. A live webcast will be available from November 18 at 3:00 AM ET, with on-demand access until November 19 at 12:00 PM ET.

Immuneering Corporation (Nasdaq: IMRX) successfully completed its upsized IPO, raising $129.4 million in gross proceeds, providing funding into 2024. The company expects to file an IND application for IMM-1-104, a dual-MEK inhibitor targeting RAS mutant tumors, in Q1 2022. Financial results for Q3 2021 show a cash position of $159.6 million, research expenses of $6.2 million, and a net loss of $8.5 million or $0.47 per share. The company is focused on advancing its oncology pipeline and presented promising preclinical data for IMM-1-104.

Immuneering Corporation (Nasdaq: IMRX) has revealed promising preclinical data for its lead product candidate, IMM-1-104, presented at the recent AACR-NCI-EORTC conference. The dual-MEK inhibitor showed extensive antitumor activity across various RAS and RAF mutant tumor models, including KRAS mutations. Notably, IMM-1-104 in combination with sotorasib demonstrated superior tumor regressions. The company plans to file an Investigational New Drug application with the FDA in Q1 2022, aiming to progress into human clinical trials in H1 2022.

Immuneering (Nasdaq: IMRX) announced promising preclinical data for its lead product candidate, IMM-1-104, a selective dual-MEK inhibitor targeting RAS mutant tumors. The data demonstrates broad antitumor activity and tolerability, to be presented at the AACR-NCI-EORTC conference from October 7-10, 2021. The company plans to submit an IND application to the FDA in Q1 2022. A Key Opinion Leader event is scheduled for October 12, 2021, to discuss these findings further.